Skip to main
CERT
CERT logo

Certara (CERT) Stock Forecast & Price Target

Certara (CERT) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 38%
Hold 38%
Sell 0%
Strong Sell 0%

Bulls say

Certara Inc. is positioned for a positive financial outlook due to its innovative biosimulation software that accelerates drug development and regulatory approval processes, significantly benefiting client access to medicines. The company's operations in key revenue markets, particularly the Americas, alongside its expansion in EMEA and Asia Pacific, support sustained growth and client demand for its modeling and simulation services. Additionally, Certara has demonstrated resilience and adaptability, enhancing its long-term production profile, which aligns favorably with ongoing trends in the pharmaceutical landscape.

Bears say

The excerpts indicate a negative outlook for Certara's stock due to declining production at the CIL plant, which suggests operational challenges that could impact revenue. Furthermore, the assignment of a conservative fixed value of $22.0 million to the Mont Sorcier Project raises concerns about the company's valuation, despite previous projections of considerable net present value. Additionally, while regulatory changes may attract investment interest, the overall impact on Certara's operational efficacy remains uncertain amid these negative developments.

Certara (CERT) has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 38% recommend Buy, 38% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Certara and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Certara (CERT) Forecast

Analysts have given Certara (CERT) a Buy based on their latest research and market trends.

According to 8 analysts, Certara (CERT) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Certara (CERT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.